<a href="https://laohu8.com/S/VSTM">Verastem</a> Reports 41% Response Rate for KRAS G12D Inhibitor in Advanced Pancreatic Cancer Trial
Verastem Oncology has announced updated efficacy and safety data from GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375 (VS-7375 outside China), an oral KRAS G12D (ON/OFF) inhibitor, for patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma (PDAC). The study was conducted in China and included 66 patients, most of whom had stage IV disease and had received at least two prior lines of anticancer therapies. At the recommended Phase 2 dose of 600 mg daily, the overall response rate $(ORR)$ among 59 efficacy-evaluable, heavily pre-treated patients was 40.7%, with a disease control rate (DCR) of 96.7%. Tumor reduction was observed in 91.5% of patients, and the four-month overall survival $(OS)$ rate was 92.2%. Median OS was not reached at the data cutoff of September 27, 2025, with a median follow-up of 5.65 months. The median progression-free survival $(PFS)$ was 5.52 months, and nearly half of the patients remained on treatment at the time of evaluation. The results were featured as a late-breaking abstract in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025, held on October 19, 2025, in Berlin, Germany.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251019413455) on October 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.